Global Idiopathic Pulmonary Fibrosis 2016-2020

SKU ID : TNV-10278897

No. of pages : 60

Publishing Date : 05-May-2016

Detailed TOC of Global Idiopathic Pulmonary Fibrosis 2016-2020

PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Disease overview
• Understanding the disease
• Pathogenesis
• Signs and symptoms
• Diagnosis
• Management
• Epidemiology
PART 06: Pipeline analysis
• Lebrikizumab
• Tipelukast
• Tralokinumab
• FG-3019
• Simtuzumab
• BMS-986020
• AF-219
• SAR156597
• BG00011
• PRM-151
• PBI-4050
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation by ROA
• Oral
• Parenteral
PART 09: Market segmentation by drug class
• Systemic corticosteroids
• Immunosuppressants
• Tyrosine kinase inhibitors
• Anti-fibrotic agents
PART 10: Geographical segmentation
• Global idiopathic pulmonary fibrosis market by geographical segmentation 2015-2020
• Idiopathic pulmonary fibrosis market in Americas
• Idiopathic pulmonary fibrosis market in EMEA
• Idiopathic pulmonary fibrosis market in APAC
PART 11: Market drivers
• Special regulatory designations for pipeline candidates
• Growth in patient population
• Unmet medical needs
PART 12: Impact of drivers
PART 13: Market challenges
• Unknown disease etiology
• Lack of proper diagnosis
• Increased use of off-label and alternative therapies
PART 14: Impact of drivers and challenges
PART 15: Market trends
• Patient assistance programs
• Increase in M&A
• Rise in public awareness
PART 16: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• Baxter International
• Boehringer Ingelheim
• F Hoffmann-La Roche
• Prometheus Laboratories
• Other prominent vendors
PART 17: Appendix
• List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Common symptoms of idiopathic pulmonary fibrosis
Exhibit 03: Other signs and symptoms of idiopathic pulmonary fibrosis
Exhibit 04: Treatment options for idiopathic pulmonary fibrosis
Exhibit 05: Drugs used in the treatment of idiopathic pulmonary fibrosis
Exhibit 06: Global idiopathic pulmonary fibrosis market: Pipeline portfolio
Exhibit 07: Global idiopathic pulmonary fibrosis market 2015-2020 ($ billions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global idiopathic pulmonary fibrosis drugs market by ROA
Exhibit 10: Global idiopathic pulmonary fibrosis drugs market segment by drug class
Exhibit 11: Global idiopathic pulmonary fibrosis market segmentation by geography 2015
Exhibit 12: Idiopathic pulmonary fibrosis market revenue by geography 2015-2020 ($ millions)
Exhibit 13: Idiopathic pulmonary fibrosis market in Americas 2015-2020 ($ millions)
Exhibit 14: Idiopathic pulmonary fibrosis market in EMEA 2015-2020 ($ millions)
Exhibit 15: Idiopathic pulmonary fibrosis market in APAC 2015-2020 ($ millions)
Exhibit 16: Key drivers
Exhibit 17: Impact of drivers
Exhibit 18: Key challenges
Exhibit 19: Impact of drivers and challenges
Exhibit 20: Key trends
Exhibit 21: Baxter International: Business segmentation by revenue 2014
Exhibit 22: Baxter International: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 23: Baxter International: Geographical segmentation by revenue 2014
Exhibit 24: Baxter International: Key takeaways
Exhibit 25: Boehringer Ingelheim: Business segmentation by revenue 2014
Exhibit 26: Boehringer Ingelheim: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 27: Boehringer Ingelheim: Geographical segmentation by revenue 2014
Exhibit 28: Boehringer Ingelheim: Key takeaways
Exhibit 29: F Hoffmann-La Roche: Business segmentation 2014 by revenue
Exhibit 30: F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 31: F Hoffmann-La Roche: Geographical segmentation by revenue 2014
Exhibit 32: F Hoffmann-La Roche: YoY growth and revenue generated from CellCept 2011-2014 ($ millions)
Exhibit 33: F.Hoffmann-La Roche: Key takeaways
Exhibit 34: Prometheus Laboratories: Product categories
Exhibit 35: Prometheus Laboratories: Key takeaways

Keyplayers in Global Idiopathic Pulmonary Fibrosis 2016-2020

Baxter International, Boehringer Ingelheim, F.Hoffmann-La Roche, Prometheus Laboratories, Afferent Pharmaceuticals, Amgen, Biogen, Bristol-Myers Squibb, Cipla, FibroGen, Gilead Sciences, GlaxoSmithKline, GNI Group, Horizon Pharma, ImmuneWorks, MediciNova, MedImmune (subsidiary of AstraZeneca), Novartis, Pfizer, Promedior, ProMetic Life Sciences, Sanofi, Shionogi, Zai Lab.
market Reports market Reports